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ABSTRACT 
 
Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by proteolytic 
cleavage of its N-terminus. The unmasked N-terminal peptide then binds to the transmembrane bundle, 
leading to activation of intracellular signaling pathways associated with inflammation and cancer. 
Recently determined crystal structures have revealed binding sites of PAR2 antagonists, but the binding 
mode of the peptide agonist remains unknown. In order to generate a model of PAR2 in complex with 
peptide SLIGKV, corresponding to the trypsin-exposed tethered ligand, the orthosteric binding site was 
probed by iterative combinations of receptor mutagenesis, agonist ligand modifications and data-driven 
structural modeling. Flexible-receptor docking identified a conserved binding mode for agonists related 
to the endogenous ligand that was consistent with the experimental data and allowed synthesis of a novel 
peptide (1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV) with higher functional potency than SLIGKV. The 
final model may be used to understand the structural basis of PAR2 activation and in virtual screens to 
identify novel PAR2 agonist and competitive antagonists. The combined experimental and 
computational approach to characterize agonist binding to PAR2 can be extended to study the many 
other G protein-coupled receptors that recognize peptides or proteins. 
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INTRODUCTION 
Protease-activated receptor 2 (PAR2), a G protein-coupled receptor (GPCR), is one of four members of 
the protease-activated receptor family (PAR1–4). Protease-activated receptors have a unique activation 
mechanism where proteolytic cleavage of the N-terminus is required to reveal a tethered ligand that 
binds intramolecularly and triggers receptor signaling.1 Endogenous activation of PAR2 by the protease 
trypsin2 exposes the tethered peptide S36LIGKV–, which activates several different G protein-mediated 
signaling pathways including Ca2+ mobilization. The PAR1 subtype is also activated by trypsin to reveal 
a distinct tethered ligand S42LLFRN– and has an overall 37% sequence identity with PAR2.3, 4 PARs are 
involved in a wide range of physiological processes and have been implicated in a number of diseases. 
However, the only drug currently targeting the protease-activated GPCRs is the PAR1 antagonist 
Vorapaxar, which was approved for prevention of thrombosis.5 The PAR2 subtype has been shown to 
play roles in pain, migraine,6, 7 cancer,8, 9 inflammation10, 11, and obesity,12 as well as metabolic and 
cardiovascular diseases.13, 14 For these reasons, PAR2 has attracted great interest as a therapeutic target, 
but drug development has been challenging due to the unusual activation mechanism and difficulties in 
identifying small-molecule ligands of the target.  
 
A major breakthrough for structure-based drug design was the recent determination of atomic resolution 
crystal structures for two PAR subtypes. In 2012, a human PAR1 structure was obtained,15 which 
revealed the binding mode of the antagonist vorapaxar. More recently, crystal structures of human PAR2 
in complex with two different antagonist ligands (AZ8838 and AZ3451) were determined.16 The three 
PAR antagonists, co-crystallized with their corresponding receptors, bind in distinct pockets. AZ3451 is 
a non-competitive antagonist of PAR2 and acts as a negative allosteric modulator. It occupies a site that 
is formed by transmembrane (TM) helices 2, 3, and 4 and faces the lipid bilayer whereas the antagonists 
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Vorapaxar (PAR1) and AZ8838 (PAR2) bind in two different pockets within the TM bundle of their 
receptors. Despite these breakthroughs in structure determination for PARs, the mechanism of activation 
by the tethered peptide agonists remains unclear. The synthetic hexapeptide corresponding to the last six 
amino acids of the human PAR2 tethered ligand, SLIGKV, is itself an agonist,17 indicating that 
interactions with the cleaved N-terminus are required for receptor activation. Understanding of how 
peptides and mimetics thereof (e.g. 2-furoyl(2f)-LIGRL-NH2
18, 2f-LIGRLO-NH2
19, and GB11020, 21) 
bind to human PAR2 would facilitate design of small molecule ligands, which could be developed into 
future therapeutics. However, as reflected by a community-wide assessment of GPCR structure 
prediction, modeling of peptide binding is very challenging due to the size and flexibility of such ligands 
and their interactions with the highly variable loop regions.22 Predictions of agonist recognition by 
PAR2 have relied on molecular docking to homology models, which has resulted in several different 
potential binding modes.23, 24 Even though atomic resolution structures of PAR2 are now available, 
modeling of the agonist-bound state is limited by that they were determined in an inactive conformation 
and the identified binding pockets are too small to accommodate any of the available peptide agonists. 
 
Herein, we combined site-directed mutagenesis of human PAR2 with chemical variation of the peptide 
ligands and computational modeling to predict the binding mode of agonist peptide SLIGKV. In 
combination with functional assays this approach identified the orthosteric site and key interactions of 
SLIGKV. Molecular docking calculations guided by the experimental data were used to generate a 
model of SLIGKV bound to PAR2 consistent with the experimental data. Models obtained via a ligand-
based approach, that exploited similarities between synthetic PAR2 ligands and AZ8838, further 
corroborated the proposed binding mode. Our findings highlight interactions of the human PAR2 
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receptor that are important for agonist and antagonist design, which was used to guide discovery of a 
novel, highly potent and selective PAR2 agonist.  
 
RESULTS AND DISCUSSION 
 
Mapping of SLIGKV-PAR2 interactions by mutagenesis. To map interactions between the N-
terminal region S36LIGKV– and PAR2, we employed an extensive, combinatorial experimental strategy, 
that introduced point mutations in both receptor and agonist. Previous studies have either focused 
exclusively on mutagenesis of the TM regions of the receptor,24 mutagenesis of the tethered ligand,25 
mutagenesis of the peptide,26, 27 or extracellular loop 2 (ECL2).28, 29 In this work, a total of 24 different 
point mutations were made in PAR2, and 26 different peptides were evaluated in a Ca2+ mobilization 
functional assay. The screened receptor mutants were selected based on the available PAR2 crystal 
structure and covered the occluded binding site of AZ8838 as well as the neighboring pocket facing the 
extracellular region. Complementary modifications to the peptide agonist were also designed (Figure 
S1). The receptor mutations did not affect receptor expression and only peptides selective for PAR2 
were considered (Figure S2). The 1321N1 cell line used in this study has endogenous levels of PAR1 
expression. Therefore, the presented lack of activity of these peptides shows that there are no off-target 
effects, including no PAR1 activity. Competition binding assays using [3H]-GB110 and a selection of 
peptides from this study were performed on wild type (WT) receptors (Figure S3 and Table S1). In these 
cases, peptide binding affinity had the same rank order as potency, consistent with previous results using 
a [3H]propionyl-2fLIGRLO probe and unlabeled SLIGKV, SLIGRL, and 2f-LIGRLO peptides.19 
However, determination of binding affinity at mutant PAR2 is challenging due to the lack of an high 
affinity endogenous agonist that can be labeled. In a recent study characterizing PAR2 receptor 
mutants,24 eight receptor mutants were tested against 2f-LIGRLO(dtpa)-NH2 and although saturation 
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binding affinity was comparable with calcium assay potency, the most functionally significant could not 
be fully probed as high enough concentrations of labeled ligand could not be reached. In the absence of 
a high affinity endogenous ligand mimetic, this mutagenesis study of the PAR2 receptor, like others 
before it, 24, 26, 30 was performed by monitoring calcium signaling. It should be noted that a limitation of 
this approach is that functional potency does not always correlate with affinity as mutants could alter 
receptor dynamics that influences interactions with intracellular effectors without affecting binding. For 
example, mutations had much smaller effects on binding affinity compared to potency in a recent study 
of PAR1.31  
 
The functional calcium potency readout allowed identification of specific receptor-agonist interactions 
necessary for activation. Nine receptor mutations led to a >10-fold reduction in potency of SLIGKV 
compared to the effect at WT receptor (Table 1 and Figure 1a). SLIGKV produced no response at the 
highest concentrations tested for the D228NECL2, H310A6.58, and Y323A7.32 mutants (superscripts 
represent generic residue numbering system for GPCRs),32 corresponding to a drop in potency of >342-
fold. Although synthetic peptides SLIGKV, SLIGRL (the rat sequence) and mimetics thereof are 
extensively used to improve understanding of the activation mechanism of the PAR2 receptor,8, 17-19 
activation by endogenous agonist trypsin was also considered to confirm the relevance of our findings. 
WT and mutant PAR2 receptors were screened for trypsin-induced activation (Figure S4 and Table S2) 
and identified that modification of the same receptor residues (Y1563.33, D228ECL2, H3106.58, and 
Y3237.32) had the largest effect irrespective of protease- or peptide-induced activation of PAR2. The 
residues that upon mutation led to the largest changes in activity were hypothesized to form key 
interactions with the peptide and provided a starting point for experiment-guided structure-based 
modeling of its binding mode (Figure 1b). 
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Attempts to model SLIGKV bound to PAR2 using the (rigid) receptor conformation represented by the 
crystal structure indicated that it was not possible to obtain a binding mode consistent with all the 
experimental data. The mutagenesis data showed that the peptide agonist interacts with residues in two 
distinct pockets. This is illustrated in Figure 1b, which depicts the two subpockets of the proposed 
orthosteric site, comprising of an entry point from the extracellular space (cyan) and the occluded 
AZ8838 binding pocket (red), which is closed off by H227ECL2 and Y3267.35 (Figure S5). Therefore, in 
order to explore potential peptide binding modes, extensive molecular docking to the PAR2 crystal 
structure (PDB code 5NDD)16 was performed with AutoDock.33 To facilitate accommodation of the 
agonist, several of the residues identified as important by mutagenesis (H3106.58, Y3237.32, and Y3267.35) 
were considered flexible during the docking simulations. SLIGKV showed a modest decrease in potency 
when H227ECL2 and Y3116.59 were mutated to Ala (3- and 6-fold respectively, Table 1), but including 
flexibility for these side chains allowed the peptide to access both pockets of the proposed orthosteric 
site. In addition, Q233ECL2 was also considered flexible to enlarge the entrance route for SLIGKV. A 
total of 10,000 models, each with a unique receptor and ligand conformation, were generated. The 
resulting binding modes (Figure 2) were analyzed by hierarchical clustering to identify those that agreed 
with the experimental data. An overview of the structure-based modeling strategy is shown in Figure S6. 
A first cluster analysis of the peptide conformations was performed by applying an RMSD threshold of 8 
Å and clusters that captured the expected overall binding mode of the peptide were identified. As the 
SLIGKV peptide is endogenously tethered to the receptor, solutions that did not have the C-terminus 
facing the extracellular surface were excluded. This criterion reduced the number of models from 10,000 
to a single cluster of solutions containing 4625 structures (Figure 2).  
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Interactions with D228ECL2 and Y821.39 anchor SLIGKV in the binding site. D228ECL2 is part of the 
AZ8838 binding pocket (Figure 1b) and forms a hydrogen bond to the imidazole ring of the antagonist 
in the crystal structure (Figure S5).16 D228ECL2 is conserved in all four PARs and has been reported as a 
key interacting partner in PAR1 activation.15, 31 As it is the only buried negatively charged residue facing 
the predicted orthosteric site, we hypothesized that D228 forms a salt bridge with the N-terminal charge 
of SLIGKV. The D228AECL2 mutation led to a large decrease in potency (124-fold), suggesting that 
D228ECL2 is a key interacting partner of SLIGKV (Table 2). Similarly, the D228NECL2 mutation, lacking 
the side chain charge, but maintaining the size of the residue lost >342-fold in activity, supporting that 
the interaction with the charge is important. The significance of interactions with D228ECL2 was further 
probed by testing modified peptide N-(3-OH-2-Me-propanoyl)-LIGKV, which lacks the charged N-
terminal amine functionality of SLIGKV (Figure S1). Reduction in potency was observed for the 
combinations of SLIGKV/D228AECL2 (166-fold) and N-(3-OH-2-Me-propanoyl)-LIGKV/WT (36-fold), 
suggesting that both D228ECL2 and the N-terminal charged moiety are key for activity. Based on these 
results, the ensemble of 4625 models was filtered to exclude the structures that did not have a hydrogen 
bond between the N-terminal nitrogen and the D228ECL2 side chain carboxylate (>3.5 Å between N and 
O). This criterion reduced the number of candidate models to 611 (Figure 2). AZ8838 also forms a 
hydrogen bond to Y821.39 in the crystal structure (Figure S5), which provided a potential candidate to 
interact with the hydroxyl group of the N-terminal serine. Removing the side chain hydrogen bond 
donor of the agonist (ALIGKV) led to a 9-fold decrease in potency compared to SLIGKV (Table 2) and 
a similar 5-fold decrease in potency of SLIGKV was observed when the hydroxyl group was removed 
from Y821.39 (Y82F). If the N-terminal charge of the peptide was removed (N-(3-OH-2-Me-propanoyl)-
LIGKV) together with removal of the hydrogen bonding capacity of Y821.39 (Y82F) an even larger 
decrease in potency was observed (66-fold), suggesting that loss of multiple polar interactions has an 
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additive effect in this pocket. As the N-terminus cannot interact with both D228ECL2 and Y821.39 based 
on their position in the crystal structure, these experiments suggested that the serine hydroxyl of 
SLIGKV forms a hydrogen bond with Y821.39. 
 
Hydrophobic side chains in position two and three of SLIGKV are important for potency. Leucine 
and isoleucine at position two and three of the peptide agonist were modified to assess the size of the 
pockets available to these residues (Table 3 and Figure 3a). Alanine substitution of the leucine in 
position two of SLIGKV resulted in loss of functional activity at all concentrations tested. In contrast, 
increasing the size of the side chain to a cyclohexylalanine (Cha) improved potency by 2-fold. Larger 
variants of the side chain such as homophenylalanine (Hph) and indanylglycine (Igl) resulted in a loss of 
potency (27- and 18-fold, respectively) (Figure 3a). The importance of the leucine residue was further 
exemplified by alanine substitution of the last four amino acids (SLAAAA), which produced only a 61-
fold drop in potency compared to SLIGKV (Table 3). Consistent with an extensive study of PAR1 and 
PAR2 peptide agonists,26 we found that leucine at position two of SLIGKV was vital for PAR2 
activation and specificity. Some designed peptides e.g. SFIGKV, SWIGKV, and S[Phe(3,4-
diChloro)]IGKV, were excluded as they showed a response in the parental cell line and were suspected 
of having PAR1 activity. At position three, a bulky hydrophobic side chain was also found to be 
favorable, as alanine substitution caused a 17-fold loss of potency. A small increase in side chain size to 
cyclohexylglycine (Chg) or methionine improved (3-fold) and maintained potency, respectively. 
However, as in the case of position two, the pocket size was limited. Tryptophan caused a 43-fold 
reduction in potency and 2-napthylalanine (2Nal) and O-tert-butyl threonine (Thr(tBu)) substitutions led 
to >342-fold loss of activity (Figure 3a). The data therefore supported that both positions two and three 
of SLIGKV were buried in the orthosteric site. This result was reproduced by the selected cluster of 
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docking solutions, but among the 611 models different hydrophobic pockets were explored by the 
leucine and isoleucine residues. 
To investigate which subpockets of the orthosteric site accommodate positions two and three of 
SLIGKV, the modified peptides S[Cha]IGKV and SL[Chg]GKV were screened against PAR2 mutants 
(Table 4). The fold change in potency of each peptide compared to SLIGKV was calculated at each 
receptor and the receptor mutations that caused the largest changes are shown in Figure 3b. The most 
striking results from these experiments were those obtained for the Y326A7.35 mutant. In the case of 
S[Cha]IGKV, a 2-fold improvement in potency compared to SLIGKV was observed at WT whereas a 
much larger 15-fold increase was obtained for Y326A7.35. In contrast, SL[Chg]GKV showed similar 
improvements of potency for WT and the Y326A7.36 mutant. A comparable, but not as pronounced, 
difference for S[Cha]IGKV was observed for the neighboring residue Y3237.32 (Y323A). These results 
suggested that the second residue of SLIGKV occupies a pocket formed by Y3237.32 and Y3267.35, in 
which the larger Cha side chain could be better accommodated if either of these residues were mutated 
to an alanine. Concentration-response curves of SLIGKV, S[Cha]IGKV, and SL[Chg]GKV at WT and 
mutants Y323A7.32 and Y326A7.35 are shown in Figure S7. No corresponding strong correlations were 
identified for SL[Chg]GKV at the screened mutants (Figure 3b). This could be explained as the pocket 
for the third residue of SLIGKV is likely located closer to the extracellular surface and ECL2 of the 
receptor and could hence be more flexible than those occupied by the first two residues. The ensemble 
of 611 remaining models was clustered based on the positions of the leucine and isoleucine residues of 
SLIGKV using an RMSD threshold of 4 Å (Figure S6). A total of 18 clusters were obtained and these 
poses were visually inspected and filtered primarily based on interactions with Y3237.32 and Y3267.35 
(Figure 4). The fifth cluster with 64 models showed placement of the leucine in a pocket composed of 
Y3237.32 and Y3267.35 and the isoleucine was positioned in a pocket in the vicinity of Y1563.33, 
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L230ECL2, and I3146.62, which was consistent with the experimental results for the receptor mutants. A 
representative model from this cluster is shown in Figure 4. 
 
Interaction with E232ECL2 at the receptor surface. If E232ECL2 in ECL2 was mutated to an alanine 
(E232AECL2) or if only the charge was removed (E232QECL2), there was a 7 and 8-fold loss in SLIGKV 
potency respectively (Table 5). A larger 16-fold change in SLIGKV potency was observed with charge 
reversal to a positively charged arginine (E232RECL2/N222QECL2, Table 5, Figure 5a and 5c). The 
E232RECL2/N222QECL2 mutant was already available from a prior study and the single N222QECL2 
mutation, located in ECL2, did not have a significant effect on SLIGRL potency in calcium signaling 
assays.16 A charge reversed peptide (SLIGEV) displayed the opposite activity pattern to SLIGKV. 
SLIGEV had the lowest potency at WT and the neutral mutants (E232AECL2 and E232QECL2), whereas it 
was most potent on the E232RECL2/N222QECL2 mutant receptor, as salt bridge formation was then 
possible (Table 5, Figure 5b and 5c). Removal of the lysine charge in the peptide agonist (SLIGAV) 
showed smaller effects at the E232ECL2 mutants and the pattern of regaining potency was not observed 
with the E232RECL2/N222QECL2 mutant (Table 5, Figure 5c). The mutagenesis data therefore suggested 
that there is a salt bridge between the lysine of the peptide and E232ECL2. A previous study also 
highlighted the importance of E232ECL2 in peptide activation of the rat PAR2 receptor.28 Furthermore, a 
similar charge reversal experiment for PAR1 reached the same conclusion that SFLLEN gained back 
activity on the corresponding (E260RECL2) mutant receptor compared to the SFLLRN peptide at WT.34 
No charge-charge interactions between the lysine of the peptide and E232ECL2 were found among the 
remaining 64 models of PAR2-SLIGKV. This appeared to be due to the conformation of ECL2, which 
oriented the side chain away from the entry point of the proposed orthosteric site. To explore if this 
interaction could be formed, refinement was performed for a representative model using MODELLER,35 
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which demonstrated that the charge-charge interaction was feasible after only small rearrangements of 
the receptor binding site, ECL2, and peptide. This resulted in our final model of SLIGKV bound to 
PAR2 based on molecular docking (Figure 6).  
 
Analysis of binding modes for synthetic PAR2 ligands and design of potent novel agonists. Further 
validation of our model for agonist binding was carried out by analyzing synthetic PAR2 ligands. In 
parallel with the molecular docking study, a ligand-centric approach was employed to compare the 
binding modes of SLIGKV to a series of other agonists (Figure 7). The key pharmacophoric groups of 
SLIGKV and previously reported PAR2 ligands 2f-LIGRLO, GB110, and GB88 were assumed to have 
overlapping binding modes. This placed the heterocyclic groups of the synthetic ligands in the same 
position as the N-terminus of SLIGKV. Based on the mutagenesis experiments, which indicated that 
AZ8838 mimics the polar interactions made by the N-terminus of the endogenous peptide, the imidazole 
group of AZ8838 would overlap with the heterocyclic groups of 2f-LIGRLO, GB88, and GB110 (Figure 
7). To construct a shape-based overlay with SLIGKV using this ligand-based approach, a 
conformational search for GB88 was performed as it had the lowest number of rotatable bonds among 
the ligands, which reduced the number of potential poses to consider. The resulting ensemble was 
filtered using the program ROCS36 to identify conformations that matched the shape of AZ8838 and 
carbon atoms placed in positions hypothesized to be occupied by positions two and three of SLIGKV in 
the binding site. An overlay of the best fitting pose of GB88 to the PAR2 crystal structure (PDB code 
5NDD16) displayed clashes with Y3116.59, Y3237.32, and Y3267.35. Optimization of the complex with 
GB88 placed in the binding site using the program Prime37 demonstrated that the predicted conformation 
could be accommodated after rearrangements of a number of protein side chains. Y3116.59, Y3237.32, and 
Y3267.35 showed a heavy atom RMSD of 2.2 Å, 4.2 Å and 1.67 Å, between the experimental and 
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optimized receptor structures, respectively. In agreement with the molecular docking results, this second 
model suggested significant side chain rearrangements for Y3116.59, Y3237.32, and Y3267.35 between the 
AZ8838- and the agonist-bound complexes. The first four residues of SLIGKV and 2f-LIGRLO could 
also be placed in this model without clashes by using a shape-based alignment to the predicted binding 
conformation of GB88. The heterocycles of GB88 and 2f-LIGRLO overlapped with both the imidazole 
group of AZ8838 and the N-terminal part of SLIGKV in our model.  
 
Analysis of the ligand-based shape alignment in relation to the PAR2 complex structure with AZ8838 
suggested that there was an additional pocket in the receptor, occupied by the 4-fluoro-2-propylphenyl 
moiety of AZ8838, that was not utilized by SLIGKV or the agonist ligands. Based on this observation a 
hybrid compound was designed, to challenge the predicted binding mode, by combining the 2nd–6th 
residue from the peptide sequence of SLIGKV with the benzyl-heterocyclic moiety of AZ8838 (Figure 
7). A 2-furoyl-LIGKV compound (R1-LIGKV) analogous to 2-furoyl-LIGRLO was obtained to confirm 
that the serine could be replaced by a heterocycle whereas 1-methyl-1H[1,2,3]triazole-4-yl-LIGKV (R2-
LIGKV) and 1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV (R3-LIGKV) were synthesized to probe 
extensions into the novel pocket (Figure 8a). Replacing the N-terminus of SLIGKV with furan improved 
potency by 18-fold to pEC50=7.30±0.06 (Figure 8b), in agreement with previous results of GB110 and 
2f-LIGRLO-NH2.
20, 21, 38 The use of a triazole moiety that extended further into the pocket with a methyl 
and benzyl group also resulted in highly potent agonists (pEC50=7.51±0.06 and 7.30±0.07 respectively, 
Figure 8b). Thus, our model facilitated the design of novel peptide agonists that were more potent than 
SLIGKV. This result also confirmed that the space identified in the model of SLIGKV bound to PAR2 
could be exploited in agonist design and corroborates positioning of the N-terminus next to the occluded 
AZ8838 binding pocket. Considering that the rodent-derived peptide SLIGRL is more potent than 
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SLIGKV at human PAR239, the potencies of the designed peptides could likely be further improved by 
replacing its lysine with an arginine. 
 
Comparison of the binding modes obtained independently from the ligand-centric and molecular 
docking protocol, respectively, showed that the same subpockets were explored by the N-terminus and 
hydrophobic side chains in positions two and three of SLIGKV (Figure S8). Docking of 1-benzyl-
1H[1,2,3]triazole-4-yl-LIGKV to the receptor model obtained from the docking protocol resulted in 
poses consistent with the predictions made for the SLIGKV peptide (Figure 8c) as did GB110 and GB88 
(Figure S9). In addition, docking a series of peptides with modifications in the third position (SLMGKV, 
SL[Chg]GKV, and SLWGKV) resulted in poses consistent with that predicted for SLIGKV and were in 
agreement with experimental data (Figures S10–S12). The cyclohexylglycine moiety of SL[Chg]GKV 
fitted neatly into the isoleucine pocket whereas the larger tryptophan side chain of SLWGKV was more 
constrained due to clashes with L2094.60, Q214ECL2, and F2435.39, which was consistent with the lower 
activity of this substitution. Therefore, the novel model of the agonist-bound state of PAR2 allowed 
docking of modified peptide agonists as well as non-peptide agonists (GB110 and GB88) and the same 
binding mode was maintained throughout, providing a consistent hypothesis for agonist recognition. 
Unlike other GPCRs, the endogenous ligand of PAR2 is tethered and so there is no orthosteric ligand 
that can be used exogenously. This leads to difficulties in pharmacological characterization of the 
receptor in, for example, binding experiments or antagonism studies of the orthosteric binding site. The 
recognition that GB110 binds in a manner consistent with SLIGKV suggests that this small molecule 
tool compound can be used as a surrogate orthosteric ligand of PAR2 in future studies. 
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Novel model of SLIGKV bound to PAR2. The disclosure of the first PAR2 crystal structure revealed 
the binding site of antagonist AZ8838 but was unable to identify the orthosteric binding site as it was not 
possible to crystalize complexes with agonist compounds. The novel model of agonist binding to PAR2 
presented herein positions SLIGKV in the orthosteric site of PAR2 identified via mutagenesis (Figure 6). 
It provides structural insights into agonist-induced conformational changes, identifying that 
rearrangements of H227ECL2, E232ECL2, Y3237.32, Y3267.35, and H3106.58 in the antagonist-bound co-
crystalized structure are necessary to accommodate SLIGKV. The N-terminus of the peptide interacts 
with Y821.39 and D228ECL2, suggesting that the “gate-keeper” residue H227ECL2 must rearrange to allow 
the agonist to access the buried pocket accommodated by AZ8838. Cheng et al.16 proposed that AZ8838 
occupies an allosteric site. Our study indicates that the compound binds in the orthosteric site, 
mimicking the interactions of the N-terminus of SLIGKV and thus acts as a competitive antagonist. The 
second residue of SLIGKV was predicted to be anchored in a pocket created by Y3237.32 and Y3267.35. 
Optimization of the interaction between the lysine to interact with E232ECL2 led to some repositioning of 
the third and fourth residues of SLIGKV.  In our final model, a hydrophobic pocket for the third residue 
is delimited by M2395.35, Y1563.33, L2094.60, L230ECL2, F2435.39, L3076.55, and Y3116.59. The C-terminal 
valine of SLIGKV was predicted to bind in a pocket delimited by V61N-term, D62N-term, S65N-term, 
V229ECL2, Y3237.32, H3106.58, and I3146.62, but it should be noted that interactions in this region are 
expected to be dynamic. The key interactions made by the peptide in our final model are summarized in 
Figure 9.  
 
In several previous studies, prediction of ligand binding modes for PAR2 ligands was constrained to 
using homology models based on templates with low sequence identity, e.g. bovine rhodopsin23, 24, 39  
and human ORL-1 (nociceptin/orphanin FQ receptor)23, 24, 40  withTM sequence identities of 21% and 
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29%, respectively. Homology models based on these templates will have large errors in the ECL2 and 
relative orientation of TM helix 7, making it difficult to obtain an accurate structure of the binding site. 
The difficulties in obtaining a consistent binding mode for PAR2 agonists has been highlighted by a 
number of studies that used homology models based on templates with low sequence identity.24, 39, 40  
Suen et al.24 recently identified residues important for 2f-LIGRL-NH2 binding based on mutagenesis 
(e.g Y821.39, Y1563.33, D228ECL2, Y3116.59, Y3267.35, and L3307.39) and primarily docked this compound 
to a rhodopsin-based homology model to identify potential binding modes. Although experimentally the 
study found a similar set of residues to be important for activation of PAR2, the binding mode predicted 
for 2f-LIGRL-NH2 is fundamentally different from that proposed in this study for SLIGKV and similar 
synthetic agonists. As demonstrated by the ligand-based alignments made in this study, the similarities 
between SLIGKV and 2f-LIGRL-NH2 suggest that these agonists should have a conserved binding 
mode. The present model predicted that the N-terminus is positioned close to both Y821.39 and D228ECL2 
whereas these residues appear to be located in distinct pockets in the homology model based on 
rhodopsin.24 Due to differences in ECL2 of the rhodopsin-based model, D228ECL2 is facing into the 
extracellular space and so was previously predicted to interact with the arginine residue of 2f-LIGRL-
NH2 (equivalent to the lysine of SLIGKV). In addition, the C-terminal leucine of 2f-LIGRL-NH2 
(corresponding to the valine in SLIGKV) was predicted to interact with Y821.39 whereas we position the 
N-terminal moiety in this region. The former option was obtained as one of our docking solutions in the 
PAR2 structure, but was discarded because of the constraint that the C-terminus of the peptide must 
extend to the extracellular space to be consistent with the endogenous tethered ligand. The PAR1 crystal 
structure provided a better template for PAR2 homology modeling,24 based on high TM sequence 
identity (44%), but the binding site conformation may not be relevant for PAR2 as it was determined in 
complex with a PAR1 selective antagonist (vorapaxar). In addition, a homology model based on PAR1 
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primarily differs from the PAR2 crystal structure in ECL2 and TM helices 5 and 6. Therefore, even 
though the PAR2 crystal structure was also determined in an inactive conformation,16 it represented an 
improved starting point for modeling. The structure brought the occluded binding pocket occupied by 
AZ8838 to our attention and demonstrated that D228ECL2 could form key interactions in this region. 
However, it should be emphasized that the crystal structure alone provided few clues on the interactions 
with SLIGKV. The constraints derived from the mutations and modified peptides were crucial in the 
modeling process as docking poses were selected based on these experiments.   
 
In light of the new PAR2 crystal structures, an extensive array of mutagenesis data generated for this 
GPCR has been placed into structural context for the first time. In support of the previous studies on 
modification of peptide agonists, we report the need for a charged or heterocyclic moiety at the amino 
terminus17, 41, the importance of the leucine at position two,27 and improved potencies for larger 
hydrophobic side chains (e.g. Cha and Chg) at positions two and three.26 Our experimental data also 
align well with other receptor mutagenesis studies which are summarized in Figure S13 and Table S3. In 
agreement with Suen et al.24, mutations of 5 receptor residues (Y821.39, Y1563.33, D228ECL2, E232ECL2, 
and Y3267.35) were detrimental, suggesting these are key for activation of calcium signaling. ECL2 has 
been reported to be important for peptide recognition at PAR2 in several studies,28, 29, 42 and we 
identified a potential interaction partner in SLIGKV. The predicted structure of the PAR2-SLIGKV 
complex represents an agonist-bound state, in which the receptor backbone is in an overall inactive 
conformation. This static model cannot explain how the changes induced by binding of the peptide 
propagate toward the intracellular side, but could provide a starting point for understanding PAR2-
mediated activation of calcium and other signaling pathways at the molecular level. Future studies 
should consider effects of mutants located deeper in the transmembrane region and the influence of the 
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unique activation mechanism of PAR2 on signaling. Notably, all receptor mutations had much smaller 
effects when activated by the protease compared to the synthetic peptide. This phenomenon has also 
been detected at PAR131 and could be because the tethered ligand has a larger interaction site across the 
surface of the receptor, which could affect receptor signaling. In fact, several studies have highlighted 
that there may be differences in activation of PAR2-mediated signaling via calcium and MAP kinase 
pathways by the tethered ligand compared to peptides.25, 27, 43 To fully address this conundrum, future 
work should consider activation of multiple pathways as well as agonists with biased signaling 
properties.7, 44, 45  
 
CONCLUSIONS 
Drug discovery for PARs has been hampered by the challenges involved in development of ligands. 
Access to structural information and understanding of the interactions responsible for receptor activation 
provides opportunities for rational drug design. Our model of agonist-bound PAR2 shows that SLIGKV 
binds in an extended conformation, occupying two pockets identified in the inactive crystal structure. 
The same binding mode was maintained in models of synthetic agonists, which supports that 
interactions in both sites are necessary for receptor activation and guided design of new PAR2 agonists. 
This also revealed the structural basis of antagonism by AZ8838, highlighting that the antagonist blocks 
access to the region of the orthosteric site that recognizes the N-terminus of SLIGKV. Antagonists may 
be obtained by targeting the AZ8838 pocket, but as optimization of potency may be challenging due to 
its limited size, the novel orthosteric site identified in this work provides an attractive alternative. The 
model could be useful in future virtual screening campaigns for novel PAR2 antagonists and agonists 
and in design of experiments focused on understanding the structural basis of receptor activation. The 
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combined experimental and computational approach to characterize agonist binding modes can be 
extended to study the many other GPCRs that recognize peptides or proteins. 
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METHODS 
 
Materials. PAR2 was expressed in the recombinant 1321N1 cell line (ATCC). Plasmids containing 
PAR2 with/without single point mutations were purchased from ThermoFisher. SLIGKV and mutant 
peptide agonists (2D structures can be found in Figure S1) were purchased from ThermoFisher except 
SL[OtBu]GKV and S[Phe(3,4-diChloro)]IGKV, which were purchased from Chinese Peptide Company, 
China. All peptides had a free amino terminus and were amidated at the C-terminus. All peptides were 
>95% pure. Small molecule GB110 was synthesized as in Cheng et al.16 
 
Design of point mutations. In addition to previously available mutants of PAR216 covering the 
occluded antagonist pocket (I327L, H135Y, H227A, H227Q, D228A, D228N), reports of important 
amino acids from the literature30, 42 as well as residues lining the channel from the extracellular region 
towards the occluded binding site were selected (L230ECL2, E232ECL2.28, Q233ECL2, L3076.55, H3106.58, 
L3146.62 and L3307.39). For Y1563.33, Y3116.59, Y3237.32, and Y3267.35 both the alanine and the 
phenylalanine mutants were investigated to explore the impact of a large modification compared to 
removing the hydrogen bond capacity. The Y82F mutant was constructed to probe the importance of a 
hydrogen bond observed in the complex structure of PAR2-AZ8838. To further evaluate the effects of 
these receptor mutations, complementary point mutations were made in the SLIGKV peptide sequence 
based on initial hypotheses of how the peptide would interact with the receptor as well as previous 
studies.26, 41 
 
Transient transfection of PAR2 mutant receptors. 1321N1 cells were cultured in Dulbecco's 
Modified Eagle Medium with Glutamax-1 (DMEM) containing 10% foetal bovine serum (FBS). Cells 
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were seeded at around 40000 cells/cm3 the day before transfection. Plasmid DNA was heat inactivated at 
65 ˚C for 20 min prior to electroporation. Transient transfections of PAR2 were carried out using the 
MaxCyte STX scalable transfection system, following the standard protocol with the subsequent 
modifications. Cells were detached, washed and resuspended at 1108 cells/mL in MaxCyte 
electroporation buffer. Plasmid DNA (50 µg/mL of cells) was prepared. Cells (400 µL) were added to 
the DNA, mixed thoroughly and transferred to the OC-400 cuvette. Electroporation was performed 
using the appropriate procotol for 1321N1 cells, and the cells were then allowed to recover at 37 ˚C for 
15 min. The transfected cells were then cryopreserved in assay ready vials.  
 
Calcium mobilization assay. PAR2-induced calcium release was monitored using the Screen Quest™ 
Fluo-8 No Wash Calcium Assay Kit (AAT Bioquest), following the manufacturer’s protocol with the 
subsequent modifications. Parental and PAR2 transiently transfected 1321N1 cells were seeded in 
DMEM containing 10% FBS at 4000 cells/well/20 µL in 384-well plates (Corning #3770) and incubated 
overnight at 37 ˚C, 5% CO2. Agonists were prepared in HHBS buffer (1 HBSS, 20 mM HEPES pH 
7.4) containing 0.1% BSA, at 5 times the final assay concentration (stated in parentheses): Trypsin (0.3 
µM – 30 pM); SLIGKV, SAIGKV, SLAGKV, S[Cha]IGKV, SL[Chg]GKV, SLAAAA (1 mM – 30 
nM); SLIGEV, SLIGAV (0.3 mM – 30 nM). Cells were loaded with Fluo-8 dye loading solution and 
incubated at 37 ˚C, 5% CO2 for 30 min, and then room temperature for 30 min. The calcium assay was 
then run in a FLIPR tetra high-throughput cellular screening system (Molecular Devices) by monitoring 
the fluorescence intensity at Ex/Em = 490/525 nm. In the case of trypsin, after 30 min incubation of the 
cells with the Fluo-8 dye, DMSO (0.01%) or vorapaxar (1 µM) was added for 30 min incubation at 
room temperature prior addition of agonist. This was to ensure that the trypsin response monitored was 
PAR2 specific. Addition of DMSO/vorapaxar prior a single concentration of SLIGKV (10 µM) showed 
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that vorapaxar did not interact with the mutant PAR2 receptors. Individual concentration-response 
curves were plotted in RLU using GraphPad Prism 746 and the ‘log[agonist] vs response – variable slope 
(four parameter)’ curve fit to obtain values of potency, EC50 (concentration producing half maximal 
response) and efficacy, Emax (maximum response). Responses were then normalised as a percentage 
above the baseline measurement on the corresponding plate and combined as appropriate. EC50 data 
were converted to pEC50 (-log10 EC50) and collated to give a mean value. Results are expressed as 
mean±standard error of the mean (s.e.m.) of n independent experiments as stated in Table/Figure 
legends. For each receptor, pEC50 for the mutated peptides were compared to SLIGKV and for each 
peptide pEC50 for the mutated receptors were compared to WT receptor. To better illustrate differences 
between peptides and/or receptors the fold change was calculated based on the geometric means (EC50 
mutant/EC50 WT). If no response was obtained functionally (i.e. pEC50 is less than the highest 
concentration tested), the minimum possible value was used in place of the geometric mean and the fold 
change is expressed as greater than. 
 
Molecular docking calculations. The crystal structure of human PAR2 in complex with AZ8838 (PDB 
code 5NDD)16 was prepared for docking simulations: (1) solvent and buffer molecules, non-interacting 
ions, as well as T4 lysozyme and cytochrome b562RIL insertions were removed; (2) N- and C-termini 
were capped with acetyl (ACE) and N-methyl amide (NME) groups respectively; (3) hydrogens were 
added to the complex; (4) AZ8838 was finally removed.  Structures of peptide agonists (SLIGKV, 1-
benzyl-1H[1,2,3]triazole-4-yl-LIGKV, SLMGKV, SLWGKV and SL[Chg]GKV) were built, capped 
with NME and protonated at physiological pH using PyMol.47 Structures of GB88 and GB110 were built 
in Marvin48 and low energy conformers were obtained using the cxcalc tool. A total of 500 conformers 
were generated using the hyperfine option and optimization limit set to 2.  
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An implemented version of AutoDock33 (Release 4.2.6) was compiled to handle >32 rotatable bonds. 
Receptor flexibility was accounted for by considering multiple side chain rotamers for H3106.58, 
Y3116.59, Y3237.32, Y3267.35, H227ECL2 and Q233ECL2 during the docking calculations. Docking input 
files were prepared through the AutoDockTools (ADT) package33 using a grid of 59x67x51 points in the 
xyz dimension with a spacing of 0.375 Å. AutoGrid4 was used to generate grid maps. The Lamarckian 
genetic algorithm (LGA) was employed: the global optimization started with a population of 300 
individuals; a maximum of 10 million energy evaluations, 27,000 generations and 100 runs were set. 
100 independent screens were performed to collect a total of 10,000 poses. 
 
Cluster analysis. The results from AutoDock were collected to perform a hierarchical cluster analysis 
for the 10,000 poses. Clustering was performed by means of the Clusterizer 1.1 software49 implemented 
with the compute_rms_between_conformation.py function from the AutoDockTools (ADT) package.33  
 
Complex refinement. Modeller 9.1435 was used to refine the model obtained from flexible receptor 
docking. Loop modeling refinement was applied to optimize: (1) SLIGKV; (2) the series of side chains 
considered as flexible during docking (H3106.58, Y3116.59, Y3237.32, Y3267.35 and H227ECL2); (3) the 
protein sequence between L230ECL2–L234ECL2 to facilitate salt bridge interaction between the lysine and 
E232ECL2 in ECL2. A total of 250 models were generated, sorted by DOPE score, and visually inspected.  
 
Docking and refinement of 1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV-, SLMGKV-, SLWGKV-, 
SL[Chg]GKV-, GB110-. and GB88-PAR2. 1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV, SLMGKV, 
SLWGKV, SL[Chg]GKV, GB110, and GB88 were docked into the protein structure of the refined 
SLIGKV-PAR2 model. In contrast to the docking of SLIGKV, the protein was considered rigid during 
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the calculations and the total number of collected poses reduced to 100. Cluster analysis was performed 
by considering a standard RMSD threshold of 2 Å between the docked poses. Except for GB110 and 
GB88, Modeller 9.1435 was used to refine the selected docked model by optimizing only the peptides’ 
residues. A total of 25 models were generated, sorted by DOPE score and visually inspected.  
 
Ligand-based modeling. Conformational searches of GB88 and truncated tetrapeptide versions of 
SLIGKV (SLIG) as well as 2f-LIGRLO-NH2 (2f-LIG) were performed using MacroModel-v11.3
50 
using the OPLS3 force field in simulated water as solvent as implemented in Maestro.51 Ligand-based 
shape overlay was performed using ROCS 3.2.0.436, 52 with AZ3833 and added carbon atoms in the 
hypothesized pocket for residues two and three as a query. A refined protein model was constructed 
from the PAR2 sequence using Prime53 and 5NDD16 as a template with the GB88 model added to the 
protein template to allow for side chain rearrangement. 
 
Images. Molecular graphics were generated using the UCSF Chimera package,54 and chemical 
structures were drawn in BIOVIA Draw 16.1.55 
 
Chemical synthesis of N-terminal modifications of SLIGKV. The LIGKV sequence was set up and 
run on a Biotage Alstra SPPS synthesizer using the following method: The resin (0.65 g, 0.33 mmol, 
0.50 mmol/g) was swelled in DMF at 55°C. Fmoc deprotection by 20%Pip in DMF 2 (3+10 min) 
followed by DMF wash (5) and Amide coupling (0.2M AA in DMF, 4 equiv.) DIC (2M in 
DMF)/Oxyma (0.5 M in DMF) at 75°C for 7 min then DMF wash (5). The deprotection and coupling 
was repeated for every AA. Final Fmoc de-protection by 20%Pip in DMF x2 (3+10 min) and the resin 
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was washed with DMF (5), MeOH (5) and DCM (5). Test cleavage for 40 min in TFA/Water/TiPS 
(95:2.5:2.5) showed product by LCMS. The resin was split into four solid phase synthesis reactor vials.   
N-terminal carboxylic acids (0.33 mmol) and HATU (125 mg, 0.33 mmol) was suspensioned in DMF 
(3 mL) and DIPEA (0.1 mL, 0.57 mmol) was added. When a clear solution was obtained it was added to 
the resin (0.082 mmol) and the reaction mixtures was shaken for 1.5 h. The solutions were filtered off 
and the resins were washed with DMF (55 mL) followed by MeOH (3×5 mL). Cleavage from resin 
was carried out using pre-cooled solution of TFA/Water/TiPS (95:2.5:2.5, ~5 mL) and for 1 h 20 min. 
The cleavage mixtures were concentrated and precipitated from DEE, centrifuged, and the ether layers 
were decantated off. The precipitates were redissolved in water/acetonitrile/acetic acid (68:30:2) and 
lyophilized to obtain the crude peptides. The crude peptides were purified by HPLC and pure fraction 
was lyophilized with 2% AcOH twice to obtain the modified peptides as TFA salts.  
 
N-((3S,6S,12S,15S)-6-(4-aminobutyl)-12-((S)-sec-butyl)-3-carbamoyl-2,17-dimethyl-5,8,11,14-tetraoxo-
4,7,10,13-tetraazaoctadecan-15-yl)-1-methyl-1H-1,2,3-triazole-4-carboxamide: White solid. Yield 
12.4 mg (20%). 1H NMR (500 MHz, DMSO-d6) δ: 8.53 (s, 1H), 8.44 (d, J = 8.9 Hz, 1H), 8.27 (t, J = 
5.6 Hz, 1H), 7.93 (dd, J = 11.0, 8.5 Hz, 2H), 7.72 (d, J = 8.9 Hz, 1H), 7.68 (s, 3H), 7.39 (s, 1H), 7.03 (s, 
1H), 4.58 (td, J = 10.0, 9.8, 4.7 Hz, 1H), 4.33 (q, J = 8.1 Hz, 1H), 4.20 (t, J = 7.9 Hz, 1H), 4.09 (s, 3H), 
4.04 – 4.08 (m, 1H), 3.79 (dd, J = 16.5, 5.7 Hz, 1H), 3.65 (dd, J = 16.6, 5.6 Hz, 1H), 2.69 – 2.79 (m, 
2H), 1.91 – 1.98 (m, 1H), 1.55 – 1.75 (m, 4H), 1.40 – 1.55 (m, 5H), 1.22 – 1.35 (m, 2H), 1.03 – 1.15 (m, 
1H), 0.87 (dd, J = 9.2, 6.5 Hz, 6H), 0.78 – 0.85 (m, 12H). HRMS (ESI-QTOF): m/z [M+H]+ Calcd for 
C29H53N10O6 637.4144; Found 637.4180. 
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N-((3S,6S,12S,15S)-6-(4-aminobutyl)-12-((S)-sec-butyl)-3-carbamoyl-2,17-dimethyl-5,8,11,14-tetraoxo-
4,7,10,13-tetraazaoctadecan-15-yl)furan-2-carboxamide: White solid. Yield 15.3 mg (25%). 1H NMR 
(500 MHz, DMSO-d6) δ: 8.34 (d, J = 8.5 Hz, 1H), 8.25 (t, J = 5.7 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.86 
(d, J = 0.9 Hz, 1H), 7.83 (d, J = 8.6 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H), 7.70 (s, 3H), 7.39 (s, 1H), 7.18 (d, 
J = 2.9 Hz, 1H), 7.03 (s, 1H), 6.63 (dd, J = 3.5, 1.7 Hz, 1H), 4.47 – 4.56 (m, 1H), 4.29 – 4.37 (m, 1H), 
4.18 (t, J = 8.0 Hz, 1H), 4.08 (dd, J = 8.9, 6.6 Hz, 1H), 3.79 (dd, J = 16.6, 5.8 Hz, 1H), 3.65 (dd, J = 
16.5, 5.6 Hz, 1H), 2.69 – 2.79 (m, 2H), 1.91 – 1.99 (m, 1H), 1.56 – 1.75 (m, 4H), 1.41 – 1.56 (m, 5H), 
1.25 – 1.35 (m, 2H), 1.02 – 1.13 (m, 1H), 0.88 (d, J = 6.5 Hz, 3H), 0.78 – 0.87 (m, 15H). HRMS (ESI-
QTOF): m/z [M+H]+ Calcd for C30H52N7O7 622.3923; Found 622.3937. 
 
N-((3S,6S,12S,15S)-6-(4-aminobutyl)-12-((S)-sec-butyl)-3-carbamoyl-2,17-dimethyl-5,8,11,14-tetraoxo-
4,7,10,13-tetraazaoctadecan-15-yl)-1-benzyl-1H-1,2,3-triazole-4-carboxamide: White solid. Yield 
21.2 mg (30%). 1H NMR (500 MHz, DMSO-d6) δ: 8.70 (s, 1H), 8.46 (d, 1H), 8.27 (t, 1H), 7.89 – 8.00 
(m, 2H), 7.72 (d, 1H), 7.66 (s, 3H), 7.32 – 7.44 (m, 6H), 7.04 (s, 1H), 5.66 (s, 2H), 4.53 – 4.64 (m, 1H), 
4.28 – 4.38 (m, 1H), 4.19 (t, 1H), 4.09 (t, 1H), 3.73 – 3.84 (m, 1H), 3.61 – 3.70 (m, 1H), 2.69 – 2.80 (m, 
2H), 1.92 – 1.98 (m, 1H), 1.61 – 1.75 (m, 3H), 1.42 – 1.61 (m, 6H), 1.25 – 1.35 (m, 2H), 1.03 – 1.13 (m, 
1H), 0.76 – 0.91 (m, 18H). HRMS (ESI-QTOF): m/z [M+H]+ Calcd for C35H57N10O6 713.4457; Found 
713.4489. 
 
(S)-6-amino-N-((S)-1-amino-3-methyl-1-oxobutan-2-yl)-2-(2-((2S,3S)-2-((S)-2-((S)-3-hydroxy-2-
methylpropanamido)-4-methylpentanamido)-3-methylpentanamido)acetamido)hexanamide: White solid. 
Yield 9.7 mg (16%). 1H NMR (500 MHz, DMSO-d6) δ 8.20 (t, J = 5.7 Hz, 1H), 8.12 (d, J = 8.1 Hz, 1H), 
7.92 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 8.8 Hz, 4H), 7.62 (d, J = 8.5 Hz, 1H), 7.39 (s, 1H), 7.04 (s, 1H), 
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4.88 (s, 1H), 4.30 – 4.37 (m, 1H), 4.27 (q, J = 7.7 Hz, 1H), 4.13 (t, J = 7.7 Hz, 1H), 4.09 (dd, J = 6.8, 
8.7 Hz, 1H), 3.65 – 3.80 (m, 2H), 3.33 – 3.50 (m, 2H, one proton under water signal), 2.69 – 2.81 (m, 
2H), 2.48 – 2.53 (m, 1H, one proton under DMSO signal), 1.93 – 2.00 (m, 1H), 1.69 – 1.76 (m, 1H), 
1.64 – 1.69 (m, 1H), 1.57 – 1.64 (m, 1H), 1.46 – 1.56 (m, 5H), 1.38 – 1.46 (m, 1H), 1.25 – 1.35 (m, 2H), 
1.02 – 1.12 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.78 – 0.90 (m, 18H). (two protons under solvent signals 
assigned from COSEY). HRMS (ESI-QTOF): m/z [M+H]+ Calcd for C29H56N7O7 614.4236; Found 
614.4256. 
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FIGURES 
 
 
Figure 1. Identification of the orthosteric binding site. (a) Heat plot of fold change of SLIGKV-induced 
activation of Ca2+ mobilisation at mutant PAR2 receptors presented on a colour scale where red and 
green correspond to >10-fold drop in potency and similar effect as WT, respectively. Numerical data are 
presented in Table 1. Asterisks highlight the residues identified as important in SLIGKV-induced 
activation of PAR2. (b) Crystal structure of PAR2 (PDB code 5NDD)16 with side chains of key residues 
shown as sticks. The predicted orthosteric binding site is depicted as a surface mesh, encompassing an 
entry point from the extracellular space (cyan) and the AZ8838 binding site (red). Residues have been 
color coordinated based on their spatial arrangement. 
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Figure 2. Filtering of PAR2-SLIGKV complexes obtained from molecular docking based on expected 
placement of N- and C-termini. The 10,000 generated models were clustered and the best docked poses 
from the four largest clusters are shown. Cluster 1 was selected as the position of the C-terminal was 
facing the extracellular surface, which is compatible with a tethered endogenous peptide. Then, the 
models from Cluster 1 with a distance >3.5 Å between the serine α-amino group (-NH3+) nitrogen and 
one of the two carboxylate oxygens of D228ECL2 were discarded. Residues have been color-coordinated 
based on their spatial arrangement. Blue spheres represent the α-amino group nitrogen of the serine in 
SLIGKV.  
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Figure 3. Interactions of hydrophobic side chains in position two and three of SLIGKV. (a) Fold change 
in potency of modified peptides at WT calculated compared to SLIGKV, presented as the log 
transformed data such that more potent peptides show an increase and less potent peptides show a 
decrease. (b) The difference in fold change of potency of modified peptides at modified receptors, 
calculated compared to SLIGKV at each receptor. Peptide structures are shown in Figure S1 and potency 
data are in Tables 3 and 4. 
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Figure 4. Cluster analysis based on the second and third residues of SLIGKV (leucine and isoleucine, 
respectively) and model selection. Best docked poses from the top five clusters are depicted.  
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Figure 5. C-terminal interactions between receptor and SLIGKV. Concentration-response curves, 
measured by calcium mobilization assays, of (a) SLIGKV and (b) SLIGEV at WT (blue) and mutant 
receptors E232A (green) and E232R (magenta). Data are presented as mean±s.e.m of n=3 independent 
experiments and numerical values can be found in Table 5. (c) The fold change in potency calculated 
compared to peptide response at WT. 
 
33 
 
 
Figure 6. Refined docked model of SLIGKV in PAR2. Peptide residues and key protein side chains are 
highlighted.  
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Figure 7. PAR2 ligands SLIGKV, 2f-LIGRLO, GB110, and GB88 display similar pharmacophoric 
groups with a polar or heterocyclic motif in the first position (orange) and a hydrophobic residue in 
the second (blue) and third (green) position. The models of SLIGKV and GB88 suggested that the 
first position was overlapping with the imidazole moiety of the small molecule antagonist AZ8838 
and that none of the agonists exploited the pocket occupied by the 4-fluoro-2-propylphenyl moiety. 
New compounds were designed based on the SLIGKV sequence that probed a lipophilic extension of 
the agonist SLIGKV (yellow). 
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Figure 8. Design of novel agonists. (a) 2D structures of novel N-terminal modified peptide agonists. (b) 
concentration-response curves of calcium signaling by novel agonists at PAR2. Data are presented as 
mean±s.e.m of n=3 independent experiments. (c) Superimposed refined docked models of 1-benzyl-
1H[1,2,3]triazole-4-yl-LIGKV (R3-LIGKV, yellow) and SLIGKV (green). 
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Figure 9. Predicted binding mode of peptide agonists in PAR2. Peptide residues and relevant side 
chains are depicted as orange spheres and green ellipses, respectively. 
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TABLES 
 
Table 1. Potency data of SLIGKV peptide at WT and mutant PAR2 receptors. pEC50 values, 
measured by calcium mobilization assays, are shown as mean±s.e.m (n=3 independent 
experiments) and fold change is calculated compared to response at WT. 
 
pEC50 Fold change 
WT 6.06±0.03 1 
Y323A7.32 < 3.5 > 342 
H310A6.58 < 3.5 > 342 
D228NECL2 3.54±0.03 332 
Y326A7.35 3.69±0.04 234 
Y156A3.33 3.93±0.06 135 
D228AECL2 3.96±0.04 124 
L307A6.55 4.00±0.06 113 
Y323F7.32 4.36±0.09 50 
I314A6.62 4.7±0.1 23 
L230AECL2 4.82±0.05 17 
E232RECL2/N222QECL2 4.85±0.03 16 
E232AECL2 5.18±0.04 7 
E232QECL2 5.18±0.07 8 
Y326F7.35 5.25±0.03 6 
Y311A6.59 5.31±0.03 6 
H135Y2.64 5.33±0.05 5 
Y82F1.39 5.39±0.03 5 
H227QECL2 5.39±0.04 5 
I327L7.36 5.45±0.06 4 
Y156F3.33 5.54±0.05 3 
H227AECL2 5.60±0.05 3 
Q233AECL2/N222QECL2 5.67±0.03 2 
Y311F6.59 5.72±0.04 2 
L330A7.39 5.97±0.03 1 
 
 
Table 2. Potency data probing N-terminal interactions of peptide agonists and PAR2 receptor with 
relevant single-point mutations. pEC50 values, measured by calcium mobilization assays, are presented 
as mean±s.e.m (n=3 independent experiments). 
 
SLIGKV ALIGKV N-(3-OH-2-Me-propanoyl)-LIGKV 
WT 6.06±0.03 5.10±0.03 4.45±0.03 
Y82F1.39 5.39±0.03 4.02±0.08 3.57±0.02 
D228AECL2 3.96±0.04 < 3.5 < 3.5 
D228NECL2 < 3.5 < 3.5 < 3.5 
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Table 4. Potency data probing interactions of SLIGKV, S[Cha]IGKV, SL[Chg]GKV at mutant PAR2 
receptors. pEC50 values, measured by calcium mobilization assays, presented as mean±s.e.m (n=3 
independent experiments). 
 
SLIGKV S[Cha]IGKV SL[Chg]GKV 
WT 6.06±0.03 6.41±0.05 6.58±0.04 
Y323A7.32 < 3.5 4.40±0.05 3.60±0.04 
H310A6.58 < 3.5 4.28±0.06 3.91±0.06 
Y326A7.35 3.69±0.04 4.87±0.05 4.32±0.05 
Y156A3.33 3.93±0.06 4.35±0.05 4.09±0.06 
L307A6.55 4.00±0.06 4.72±0.05 4.58±0.06 
Y323F7.32 4.36±0.09 5.4±0.1 5.23±0.08 
I314A6.62 4.7±0.1 5.38±0.05 5.26±0.04 
L230AECL2 4.82±0.05 5.7±0.1 5.33±0.06 
Y326F7.35 5.25±0.03 5.94±0.05 5.84±0.05 
Y311F6.59 5.72±0.04 6.44±0.05 6.49±0.05 
Y156F3.33 5.54±0.05 5.96±0.06 6.08±0.06 
L330A7.39 5.97±0.03 6.85±0.06 6.53±0.05 
Y311A6.59 5.31±0.03 6.02±0.07 6.01±0.05 
I327L7.36 5.45±0.06 6.06±0.05 6.15±0.05 
 
 
Table 5. Potency data probing C-terminal interactions of peptide agonists at mutant PAR2 receptors. 
pEC50 values, measured by calcium mobilization assays, are presented as mean±s.e.m (n=3 independent 
experiments). 
  SLIGKV SLIGEV SLIGAV 
WT 6.06±0.03 4.69±0.06 5.16±0.04 
E232AECL2 5.18±0.04 4.64±0.06 4.70±0.08 
E232QECL2 5.18±0.07 4.44±0.07 4.64±0.09 
E232RECL2/N222QECL2 4.85±0.03 5.02±0.05 4.60±0.05 
 
Table 3. Potency data probing hydrophobic interactions of mutant peptide agonists and WT PAR2 
receptor. pEC50 values, measured by calcium mobilization assays, are presented as mean±s.e.m (n=3 
independent experiments). 
Peptide pEC50±s.e.m  Peptide pEC50±s.e.m 
SLIGKV 6.06±0.03  SLAGKV 4.83±0.03 
SAIGKV < 3.5  SL[Chg]GKV 6.58±0.04 
S[Cha]IGKV 6.41±0.05  SLMGKV 5.94±0.05 
S[Hph]IGKV 4.61±0.06  SLWGKV 4.43±0.07 
S[Igl]IGKV 4.81±0.06  SL[Thr(tBu)]GKV < 3.5 
SLAAAA 4.27±0.05  SL[2Nal]GKV < 3.5 
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SUPPORTING INFORMATION 
Supporting methods, Figures S1-S13, Tables S1-3, and the refined model of SLIGKV in the PAR2 
binding site in PDB format. 
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Schematic representation of the inactive (left) and agonist-bound (right) Protease-Activated Receptor 2 
(PAR2) structures: Mutagenesis in combination with assays for peptide ligands and computational 
modeling allowed identification of the PAR2 orthosteric site and agonist-induced conformational 
rearrangements. The resulting model of the binding site was used to design novel PAR2 agonists. 
 
